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Increased insulin resistance and inﬂammatory action are observed in pregnancy-induced hypertension (PIH), but similar
insulin resistance is observed also in successful pregnancy. To estimate insulin resistance and inﬂammatory activity in normal
pregnancy and PIH, serum concentrations of free fatty acids (FFA; corrected with albumin to estimate unbound FFA), monocyte
chemoattractant protein (MCP)-1, and high-molecular weight (HMW) adiponectin were measured in severe PIH patients with
a BMI less than 25kg/m2 and were measured 3 times during the course of pregnancy in women with normal pregnancies.
FFA/albumin, MCP-1, and HMW adiponectin concentrations were signiﬁcantly higher in PIH patients than in women with
normal pregnancies. The 3 measurements of FFA/albumin showed a signiﬁcant increase through the course of uncomplicated
pregnancies.Incontrast,MCP-1andHMWadiponectinweresigniﬁcantlydecreased duringthecourseofpregnancy. Theseresults
suggest that the reduced MCP-1 concentration in normal pregnancy may be a pathway to inhibit the induction of pathological
features from physiological insulin resistance and homeostatic inﬂammation.
1.Introduction
Pregnancy-induced hypertension (PIH), a leading complica-
tioninpregnancythataﬀectsthemotherandfetus,isbecom-
ing more frequent mainly because of increasing maternal age
[1].Maternalobesity,abasalconditionthatincreasestherisk
of PIH 3-fold [2], has also increased over the decades [3].
On the other hand, increased insulin resistance is observed
in PIH as well as in successful pregnancies [4–6]. In the
course of a normal pregnancy, insulin resistance is correlated
with increased maternal adipose tissue deposition [5]a n d
supports placental formation and fetal growth.
Although the placenta is a large producer of cytokines
during pregnancy [7], adipose tissue is regarded as the main
organ producing insulin resistance and related cytokines
[5, 6, 8, 9]. Recently, free fatty acids (FFA; also known as
nonesteriﬁed fatty acids (NEFA)) were shown to be media-
tors of immune and inﬂammatory actions in adipose tissue
[6, 8–13]. Although increased circulating FFA have been
observed in gestational diabetes mellitus, preterm delivery,
or other adverse maternal outcomes in pregnant subjects
[6, 9, 14, 15], increased circulating FFA have also been de-
scribed in normal pregnancy [16]. Diﬀerent pathways which
do not induce systemic inﬂammation observed in PIH [4]i n
insulin resistance remain unclear.
In this study, we measured peripheral monocyte che-
moattractant protein-1 (MCP-1), a proinﬂammatory che-
mokine that induces monocyte action leading to cell adhe-
sion and endothelial dysfunction, FFA, and high-molecular
weight (HMW) adiponectin, a major adipocytokine that
reﬂectsinsulinsensitivity,inPIHpatientsandmaderepeated
measurements of these molecules in women with normal
pregnanciesthroughoutthecourseofpregnancy.Wehypoth-
esized that an alteration of the chemokines in the inﬂamma-
tory pathway protects women with normal pregnancies, but
not PIH patients, from cardiovascular disorders in a state of
physiological insulin resistance.
2.MaterialsandMethods
2.1. Subjects. This study was reviewed and approved by the
Institutional Review Board of Nara Medical University, and2 Mediators of Inﬂammation
informed consent was obtained from each subject. For the
preliminary study, we recruited 17 nonpregnant women
with body mass index (BMI) under 25kg/m2,2 5n o r m a l
pregnant women at 28 weeks or later of gestation, and 7
severe PIH patients. The pregnant women had BMIs under
25kg/m2 prior to pregnancy. All women were East Asian,
and none were taking any medications or showed evidence
of any metabolic diseases or complications other than PIH.
Severe PIH was deﬁned as the new onset of 2 consecutive
measurements of diastolic blood pressure ≥110mmHg and
systolic blood pressure ≥160mmHg diagnosed after 20
weeks of gestation. After the preliminary study, we recruited
36 normal pregnant women for sample correction by taking
measurements 3 times throughout the course of pregnancy
(1st screening=around 12 weeks of gestation; 2nd=28
weeks; and 3rd=36 weeks) for a longitudinal study and
paired analysis. All subjects had serum samples available
for analysis and did not have gestational diabetes mellitus,
thyroid malfunction, or other complications except hyper-
tension. Proteinuria was not considered within the criteria of
this study.
All venous blood samples were obtained after an
overnight fast at routine medical examination. Serum was
separated immediately and stored at −80◦Cf o r3y e a r sf o r
the longest and 6 month for the shortest storage.
2.2. Enzyme Immunoassays. Serum FFA (mainly palmitic
acid) were measured in duplicate with a commercially
available kit (BioVision Research Products, Mountain View,
CA). The lower limit of detection was 2μM. To estimate
alterations in unbound FFA, the data were corrected with
serum albumin concentrations (FFA (μM)/albumin (g/dL))
by using the BCG albumin assay kit (BioChain, Hayward,
CA). The lower limit of detection of albumin was 0.01g/dL.
Serum HMW adiponectin level and its ratio to total
adiponectin were measured on the same 96-well plate in
duplicate using a commercially available protease-pretreated
ELISA kit (Sekisui Medical, Co., Ltd., Japan). The lower limit
of detection was 0.075ng/mL. The intraassay coeﬃcient of
variation (CV) was within ±20%, while the inter-assay CV
was not more than 15%. Serum leptin and MCP-1 con-
centrations were measured in duplicate with commercially
available ELISA kits (R&D Systems, Inc., Minneapolis, MN).
The lower limit of detection was less than 7.8pg/mL for
leptin and less than 5.0pg/mL for MCP-1. For leptin, the
intraassay CV was 3.3% at a concentration of 64.5pg/mL,
3.0% at 146pg/mL, and 3.2% at 621pg/mL, while the inter-
assay CV was 5.4% at 65.7pg/mL, 4.2% at 146pg/mL, and
3.5% at 581pg/mL. For MCP-1, the intraassay CV was 7.8%
at a concentration of 76.7pg/mL, 4.7% at 364pg/mL, and
4.9% at 1121pg/mL, while the inter-assay CV was 6.7% at
74.2pg/mL, 5.8% at 352pg/mL, and 4.6% at 1076pg/mL.
In the longitudinal study, measurement of FFA, albumin,
MCP-1, and HMW adiponectin were performed using the
techniques described above.
2.3. Statistical Analysis for Human Serum Measurement.
In the preliminary study, we compared normal pregnant
women with nonpregnant women and compared PIH
patients with normal pregnant women at 28 weeks or later
of gestation. Statistical analysis was performed using the
Mann-Whitney U-test (SPSS 15.0J; SPSS Japan Inc., Japan).
In the longitudinal study, results in respective patients
were analyzed in pairs using repeated measures of ANOVA
with the post hoc test (Bonferroni correction; SPSS 15.0J).
Statistical signiﬁcance was set at P<0.05. All values are
expressed as the mean ±SEM.
3. Results
3.1. Preliminary Study: FFA and Other Adipocyte-Derived
Inﬂammatory Factors in PIH. In the preliminary study, we
compared normal pregnant women at 28 weeks or later
of gestation with nonpregnant subjects and compared PIH
patients with normal pregnant women at 28 weeks or later
of gestation. Subject characteristics are shown in Table 1.
Diastolic blood pressure was signiﬁcantly lower in normal
pregnant subjects than in the nonpregnant subjects. Blood
pressurevaluesweresigniﬁcantlyhigherinPIHsubjectsthan
in normal pregnant women.
Serum concentrations of FFA (raw data and after cor-
rection with albumin), MCP-1, total and HMW adiponectin
(raw data and ratio), and leptin are shown in Table 1.F F A
concentrationswere signiﬁcantlyhigher inPIH subjects than
in normal pregnant women but no signiﬁcant diﬀerence
was observed between normal pregnancy and nonpregnant
controls. However, after the albumin correction (an esti-
mated value reﬂecting unbound FFA), serum concentrations
were signiﬁcantly higher in normal pregnancy than in
nonpregnant controls. Serum concentrations of MCP-1 were
signiﬁcantly lower in normal pregnant subjects than in
nonpregnant controls and were signiﬁcantly higher in PIH
than in normal pregnant subjects. HMW adiponectin con-
centrationanditsratiotototaladiponectinweresigniﬁcantly
l o w e ri nn o r m a lp r e g n a n ts u b j e c t st h a ni nn o n p r e g n a n t
subjects and were higher in PIH subjects than in normal
pregnant women. Serum leptin was signiﬁcantly increased
only in PIH patients compared to that in normal pregnant
subjects. These trends in HMW adiponectin, leptin, and
MCP-1 are similar to those in our former report that
included subjects with BMIs greater than 25kg/m2 [17];
however, the trends in total adiponectin and HMW-to-total
adiponectin ratio diﬀer from those in our previous report.
3.2. Longitudinal Study: FFA, MCP-1, and HMW Adiponectin
d u r i n gt h eC o u r s eo fN o r m a lP r e g n a n c y .Subject character-
istics are shown in Table 2. FFA concentrations were not
signiﬁcantly altered in normal pregnant women over the
course of 3 measurements: 1st screening, 97.47 ± 13.05μM;
2nd, 110.89 ± 12.78; 3rd, 120.85 ± 12.24. However, after
the albumin correction (1st screening, 3.15±0.04g/dL; 2nd,
2.57 ± 0.03; 3rd, 2.52 ± 0.03) to estimate the alteration of
unbound FFA, the value (FFA [μM]/albumin [g/dL]) was
signiﬁcantly increased throughout the course of pregnancy:
1stscreening,31.38±4.29;2nd,42.51±4.82;3rd,48.45±5.10;
P = 0.0048 (Figure 1). In contrast, MCP-1 concentrations
decreased signiﬁcantly during the course of pregnancy: 1st
screening, 154.36 ± 20.27pg/mL; 2nd, 110.56 ± 33.44; 3rd,Mediators of Inﬂammation 3
Table 1: Characteristic of the subjects and serum concentrations of the molecules.
Nonpregnant control Normal pregnancy
later than 28 weeks
Pregnancy-induced
hypertension
n 17 25 7
Gestational age at sampling (weeks) 33.2 ±0.73 2 .3 ±0.8
BMI at sampling (kg/m2)2 0 .3 ±0.42 3 .9 ±0.5∗ 24.5 ±0.6
BMI before pregnancy (kg/m2)2 0 .3 ±0.42 0 .5 ±0.42 0 .9 ±0.9
Blood pressure
Systolic 106.3 ±1.8 107.3 ± 1.8 174.8 ±2.0
Diastolic 73.1 ±1.25 8 .8 ±1.6∗ 100.3 ±2.6∗∗
MAP 84.1 ±1.17 4 .9 ±1.5∗ 107.3 ±17.9∗∗
FFA (μM) 155.62 ±29.17 153.68 ±16.23 236.54 ±31.89∗∗
Albumin (g/dL) 3.48 ±0.07 2.62 ±0.05∗ 1.92 ±0.12∗∗
FFA/Alb 41.62 ±8.50 58.82 ±5.94∗ 124.94 ±15.96∗∗
MCP-1 (pg/mL) 219.50 ±12.17 131.95 ±8.63∗ 195.41 ±27.22∗∗
Adiponectin
Total (μg/mL) 8.85 ±0.62 5.33 ±0.37∗ 6.82 ±1.00
HMW (μg/mL) 4.45 ±0.46 1.97 ±0.20∗ 3.66 ±0.62∗∗
HMW/total adiponectin ratio 0.49 ±0.03 0.36 ±0.02∗ 0.53 ±0.04∗∗
Leptin (ng/mL) 6.91 ±0.91 8.31 ±1.09 35.56 ±10.31∗∗
BMI: body mass index; MAP: mean arterial pressure; FFA: free fatty acids; MCP: monocyte chemotactic protein; HMW: high-molecular weight.
∗P<0.05 versus nonpregnant control.
∗∗P<0.05 versus normal pregnancy later than 28 weeks.
Table 2: Characteristic of the subjects of longitudinal study.
n 36
Maternal age at delivery (years) 30.9 ±0.7
Parity (times)
01 8
11 3
2o rm o r e 5
Average gestational age at sampling
(weeks+days)
1st 11+5 (8+2–14+4)
2nd 28+3 (27+2–29+5)
3rd 36+1 (35+0–37+2)
BMI before pregnancy (kg/m2)2 2 .1 ±0.6
BMI on delivery (kg/m2)2 6 .4 ±0.6
Average gestational age at delivery (weeks+days)3 9 +5 (36+6–41+3)
Infant birth weight (g) 3052.0 ±78.7
BIM: body mass index.
108.78±28.17;P<0.0001(Figure 1).HMWadiponectinwas
also signiﬁcantly decreased during the course of pregnancy:
1st screening, 3.48±0.30μg/mL; 2nd, 2.88±0.27; 3rd, 2.86±
0.25; P = 0.0001 (Figure 1).
4. Discussion
Our preliminary study showed increases of FFA (particularly
bioactive unbound FFA) and MCP-1 in lean severe PIH
patients. However, in normal pregnancy, FFA increased but
MCP-1 signiﬁcantly decreased in the serum. In longitudinal
study throughout normal pregnancy, increase of FFA and the
decrease of MCP-1 during the course have been clariﬁed.
A signiﬁcant decrease in HMW adiponectin, which may be
consistent with the physiological increase of insulin resis-
tance in normal pregnancy, was also conﬁrmed.
Fatty acids play pivotal roles in the development of
several diseases including adult metabolic syndrome [8,
10–12] and pregnancy complications such as miscarriage
[6] or preterm delivery [14], though fatty acids are also
involvedinthesuccessfulphysiologicaldistributionofenergy
in pregnancy [18]. It was recently revealed that FFA are
mediators of toll-like receptor (TLR)-4 and the NF-kappaB
pathway of macrophages within adipose tissue and are
regarded as key molecules in systemic inﬂammation, which
plays a role in type 2 diabetes and cardiovascular disease
[10, 12, 13]. As we reviewed in this journal [19], TLRs
may contribute to pregnancy pathologies. Several reports
described increased FFA in preeclampsia [6, 15] but these
reports did not estimate unbound FFA. In preeclamptic
patients, acute inﬂammation is one of the major features of
preeclampsia pathophysiology [2, 4, 6, 7, 15]. A diﬀerence
between our study and former studies is that we chose only
lean subjects, who may not show adipocyte hypertrophy.
Adiponectin was increased in our PIH subjects. We recently
reported thatincreased brain-type natriuretic peptide (BNP)
correlated with increased adiponectin in PIH [17], similar
to the ﬁndings in acute coronary syndrome [20]a n d
cardiomyopathy [21]. We also showed that BNP induced4 Mediators of Inﬂammation
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Figure 1: (a) Serum concentrations of FFA (μM)/albumin (g/dL), (b) MCP-1 (pg/mL), and (c) high-molecular weight (HMW) adiponectin
(μg/mL) during normal pregnancy and PIH (for reference; see Table 1). In normal pregnancy, samplings were performed 3 times in each
subject (see Table 2) and analyzed in pairs. Data are shown as the 90th, 75th, 50th, 25th, and 10th percentile of each measurement group.
∗P<0.05 in repeated measures of ANOVA with the post hoc test.
the release of adiponectin from cultured adipocytes in vitro
[17]. In this respect, further research is needed to reveal the
conditions of adipose tissue in PIH patients without obesity.
MCP-1 is a major chemokine and proinﬂammatory
cytokine that activates monocyte recruitment and strongly
contributes systemically to the pathology of inﬂammation. It
is now well accepted that the insulin-resistant state induces
the mitogen-activated protein kinase pathway and increases
MCP-1 secretion from adipocytes [11, 12], indicating that
MCP-1 potentiates the pathology of insulin resistance.
Increased MCP-1 was observed in pregnant women with
severe obesity [22, 23] and preeclampsia [17, 24]. Addition-
ally, MCP-1 secretion was reported from the human early
invasive trophoblast [25] .H o w e v e r ,ap e r i p h e r a ld e c r e a s e
of MCP-1 in successful human pregnancy has only been
described in a single report using multiple cytokine arrays
[26], showing a similar decrease of the serum concentration
of this molecule during pregnancy. This decrease may be a
system adaptation in humans to avoid pathologic activation
of monocytes in pregnancy-induced insulin resistance. The
only evidence to support this hypothesis was reported in
spontaneously hypertensive rats. MCP-1 expression was
increased in the kidney in rat but expression declined
signiﬁcantly after the rats became pregnant, and blood
pressure was also decreased [27]. This paper suggests the
existence of an adaptation system during pregnancy via
chemokine regulation.
The limitation of this study is that food intake was not
equalized between each sampling even though all samples
were taken after an overnight fast. FFA concentrations are
a l t e r e df o rs e v e r a ld a y sa f t e rd i ﬀerent food choices, and
albuminmaydecreasewithemesisoranemia.Alargercohort
studyormorefrequentsamplingmayreducethealterationof
the results after an unusual dietary event.
5. Conclusions
Although FFA were also increased during the course of
normal pregnancy, which may be consistent with physiolog-
ical insulin resistance, MCP-1 was decreased, which would
inhibit MCP-1-mediated pathologic inﬂammation during
the hyperlipidemic state of a successful pregnancy. FFA and
MCP-1 in adipose tissue are regarded as key molecules in
homeostatic inﬂammatory linkage. This is the ﬁrst report
suggesting a diﬀerence between pathological inﬂammation
and reasonable insulin resistance in human pregnancy.Mediators of Inﬂammation 5
Further research in adipocytokines and adipose tissue may
lead new statistics for prediction and therapy of pregnancy
complications.
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